Nanobiotix’s Strategic Financing and Clinical Expansion Signal Strong Buy Opportunity

Analyst Swayampakula Ramakanth of H.C. Wainwright maintained a Buy rating on Nanobiotix, boosting the price target to €23.00.

Swayampakula Ramakanth has given his Buy rating due to a combination of factors including Nanobiotix’s recent non-dilutive financing deal with HealthCare Royalty, which extends the company’s financial runway into early 2028. This agreement not only avoids shareholder dilution but also reflects confidence from major partners like Johnson & Johnson, who are involved in a collaboration that could yield significant future capital through milestones and royalties.
The initiation of a new clinical study by Johnson & Johnson to explore JNJ-1900 in a broader patient population further underscores the potential expansion of the drug’s market opportunity. This expansion, coupled with the favorable terms of the financing agreement, suggests that the stock is currently undervalued, presenting a strategic buying opportunity for long-term investors. The analyst believes these developments provide a strong foundation for future growth, justifying the Buy rating.